Septerna (SEPN) Total Non-Current Liabilities (2023 - 2026)
Septerna (SEPN) recorded quarterly Total Non-Current Liabilities of $191.1 million in Q1 2026, down 10.8% quarter-over-quarter from $214.3 million in Q4 2025, and up 466.7% on a YoY basis from $33.7 million in Q1 2025.
Septerna (SEPN) Total Non-Current Liabilities (2023 - 2026) Analysis & Trends
Septerna's Total Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $191.1 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 466.7% year-over-year to $191.1 million; the TTM figure through Mar 2026 stood at $191.1 million (up 466.7% YoY), while the FY2025 annual figure was $214.3 million, up 487.43% from the prior year.
- Total Non-Current Liabilities was $191.1 million for Q1 2026 at Septerna, down from $214.3 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $217.9 million in Q3 2025 to a low of $19.5 million in Q4 2023.
- Historically, Total Non-Current Liabilities has averaged $98.5 million across 4 years, with a median of $37.5 million in 2024.
- The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities jumped 87.24% in 2024, then jumped 487.43% in 2025.
- A 4-year view of Total Non-Current Liabilities shows it stood at $19.5 million in 2023, then soared by 87.24% to $36.5 million in 2024, then surged by 487.43% to $214.3 million in 2025, then slipped by 10.8% to $191.1 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $191.1 million (Q1 2026), $214.3 million (Q4 2025), and $217.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Septerna | 1.62 Bn | 1.62 Bn | - | 191.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 191.13 Mn |
| Dec 31, 2025 | 214.26 Mn |
| Sep 30, 2025 | 217.92 Mn |
| Jun 30, 2025 | 37.67 Mn |
| Mar 31, 2025 | 33.73 Mn |
| Dec 31, 2024 | 36.47 Mn |
| Sep 30, 2024 | 37.34 Mn |
| Dec 31, 2023 | 19.48 Mn |